Rebeca Vega

Followers

Following

Co-author

Public Views

Related Authors

Mohd Ridwan Abd Rahman

Universiti Malaysia Sarawak (UNIMAS)

Jean-Jacques Hublin

Max Planck Institute for Evolutionary Anthropology

Marta Florio

Harvard Medical School

Paixão-Côrtes Vanessa

Universidade Federal do Rio Grande do Sul

Cristian Araneda

Universidad de Chile

José-Miguel Tejero

University of Vienna

Freddy Bravo

Universidade Estadual de Feira de Sanana

Markus Bastir

CSIC (Consejo Superior de Investigaciones Científicas-Spanish National Research Council)

Dimuth Siritunga

University of Puerto Rico Rio Piedras

Nick Mamalis

University of Utah

Interests

Uploads

Papers by Rebeca Vega

Eficacia y seguridad del Bevacizumab (Avastín) intravítreo en la neovascularización coroidea en miopía patológica

Archivos Chilenos De Oftalmologia, 2007

Resumen: Evaluar seguridad y eficacia a corto plazo del bevacizumab intravitreo en pacientes con ... more Resumen: Evaluar seguridad y eficacia a corto plazo del bevacizumab intravitreo en pacientes con neovascularizacion coroidea (NVC) en miopia patologica sin tratamiento previo. Diseno: Serie clinica consecutiva intervencional retrospectiva. Metodos: Siete pacientes recibieron bevacizumab intravitreo (1,5 mg). Se evaluaron los efectos secundarios, cambios en agudeza visual de Snellen (AV), caracteristicas angiograficas y tomografia de coherencia optica (OCT) al mes, tres y/o ultimo mes de control post inyeccion. Resultados: No se encontraron efectos adversos. Al mes todos los pacientes presentaron desaparicion de la filtracion angiografica y resolucion del liquido subretinal en el OCT, con disminucion media del grosor central de 73,3 um(p=0,01). La AV media mejoro de 0,2 a 0,4 (p=0,02) y de 0,2 a 0,5 (p=0,02) al primer y tercer mes respectivamente. Ningun paciente requirio retratamiento. Conclusiones: El bevacizumab intravitreo es bien tolerado y se asocia con mejoria de la AV en concomitancia con regresion de los signos angiograficos y al OCT de actividad de la NVC en miopia patologica. (AU) Objective: To assess the short term efficacy and safety of intravitreal bevacizumab for myopic choroidal neovascularization (mCNV) without previous treatment. Methods: Intravitreal bevacizumab (1.5 mg) was injected into seven eyes of seven patients with mCNV in this non randomized, retrospective interventional case series. Changes in Snellen visual acuity (VA), optical coherence tomography (OCT) and fluorescein angiography (FA) were measured at 1,3 and/or last follow up month after treatment. Results: At one month all patients showed resolution of leakage from the mCNV in the FA and the mean foveal thickness on OCT images decreased 73.3 um (p=0.01). Mean VA improved from 20/100 to 20/50 (p=0.02) and from 20/100 to 20/40 (p=0.02) at 1 and 3 months post injection respectively. No retreatments were required. No major complications developed. Conclusion: Intravitreal injection of bevacizumab is well tolerated and in this small series seems to be safe and efficacious in eyes with mCNV. (AU)

Edit

Necrosis retinal aguda y necrosis retinal externa progresiva

Arch Chil Oftalmol, 2001

Edit

Naloxona aumenta la presión arterial sistémica durante la asfixia fetal: rol modulador de opioides endógenos

Rev Med Chile, Sep 1, 1985

Base de dados : LILACS. Pesquisa : 28572 [Identificador único]. Referências encontradas : 1 [refi... more Base de dados : LILACS. Pesquisa : 28572 [Identificador único]. Referências encontradas : 1 [refinar]. Mostrando: 1 .. 1 no formato [Detalhado]. página 1 de 1, 1 / 1, LILACS, seleciona. para imprimir. Fotocópia. experimental, Documentos relacionados. Id: 28572. ...

Edit

[Aldose reductase gene polymorphism and rate of appearance of retinopathy in non insulin dependent diabetics]

by Rebeca Vega and Juan Carlos Claro

Revista médica de Chile, 1999

Recent studies suggest that polymorphisms associated to the aldose reductase gene could be relate... more Recent studies suggest that polymorphisms associated to the aldose reductase gene could be related to early retinopathy in noninsulin dependent diabetics (NIDDM). There is also new interest on the genetic modulation of coagulation factors in relation to this complication. To look for a possible relationship between the rate of appearance of retinopathy and the genotype of (AC)n polymorphic marker associated to aldose reductase gene. A random sample of 27 NIDDM, aged 68.1 +/- 10.6 years, with a mean diabetes duration of 20.7 +/- 4.8 years and a mean glycosilated hemoglobin of 10.6 +/- 1.6%, was studied. The genotype of the (AC)n, polymorphic marker associated to the 5' end of the aldose reductase (ALR2) gene was determined by 32P-PCR plus sequenciation. Mutations of the factor XIII-A gene were studied by single stranded conformational polymorphism, sequenciation and restriction fragment length polymorphism. Four patients lacked the (AC)24 and had a higher rate of appearance of re...

Edit

(AC)23 [Z−2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics

by Rebeca Vega and Juan Carlos Claro

Diabetes Research and Clinical Practice, 2000

A recent case-control study suggests that the allele (AC) 23 of a variable number tandem repeat (... more A recent case-control study suggests that the allele (AC) 23 of a variable number tandem repeat (VNTR) associated to the aldose reductase (ALR2) gene could be related to early retinopathy in Type 2 diabetics. By means of a longitudinal-retrospective study, we aimed to seek for a relationship between the rate of progression of retinopathy and the (AC) 23 allele of the VNTR associated to the ALR2 gene. A random sample was obtained of 27 Type 2 diabetics (aged 68.1 910.6 years, diabetes duration = 20.79 4.8 years, mean HbA1 = 10.691.6%). The mean HbA1 was the arithmetic average of 2.2 measurements per patient per year of total glycosilated hemoglobin (Gabbay method, normal range: 4.2-7.5%). Retinopathy was graded by an Ophtalmologist in a scale from zero to four score points. The genotype of the (AC) n VNTR was determined by 32P-PCR plus sequenciation in a Perkin -Elmer laser device. The Mann-Whitney test and either 2 or Fisher's exact test were used. A PB0.05 was considered as statistically significant. The retinopathy progression rate (RPR, points ×year -1 ) was calculated by dividing the increment of retinopathy score (D Retinopathy Score, [points]), by the duration of the follow up [years]. The 12 diabetics having the (AC) 23 allele had a mean RPR 8.9 times higher (0.40 9 0.61 points × year -1 ) than the 15 patients who had alleles other than (AC) 23 (0.0459 0.099 points ×year -1 , P= 0.037). Both groups were similar with respect to: mean HbA1 (10.59 1.4 and 10.791.7%, P= 0.95), age at diagnosis (48.5+6.3 and 46.3+ 14.0 years, P = 0.81),

DownloadEdit

Rebeca Vega

Uploads

Papers by Rebeca Vega

Log In